Vaxcyte (NASDAQ:PCVX) Given Buy Rating at BTIG Research

Vaxcyte (NASDAQ:PCVX)‘s stock had its “buy” rating reiterated by investment analysts at BTIG Research in a note issued to investors on Monday, Marketbeat.com reports. They presently have a $89.00 target price on the stock. BTIG Research’s price objective would suggest a potential upside of 32.92% from the stock’s current price.

A number of other brokerages also recently weighed in on PCVX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday. Guggenheim raised their target price on shares of Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a report on Monday. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Needham & Company LLC lifted their price objective on shares of Vaxcyte from $110.00 to $122.00 and gave the company a “buy” rating in a report on Monday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $108.60.

Vaxcyte Price Performance

Shares of PCVX stock traded up $0.26 during trading hours on Monday, reaching $66.96. 11,557,993 shares of the company were exchanged, compared to its average volume of 1,552,646. Vaxcyte has a fifty-two week low of $39.87 and a fifty-two week high of $90.75. The company has a market cap of $9.96 billion, a price-to-earnings ratio of -8.78 and a beta of 1.23. The stock’s fifty day moving average is $59.28 and its two-hundred day moving average is $56.40.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same quarter in the prior year, the business posted ($1.22) earnings per share. On average, research analysts anticipate that Vaxcyte will post -8.07 earnings per share for the current year.

Insider Activity at Vaxcyte

In other news, COO Jim Wassil sold 3,477 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $61.07, for a total value of $212,340.39. Following the completion of the sale, the chief operating officer owned 155,041 shares of the company’s stock, valued at approximately $9,468,353.87. The trade was a 2.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Grant Pickering sold 16,198 shares of the business’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $55.63, for a total transaction of $901,094.74. Following the completion of the sale, the chief executive officer directly owned 453,247 shares of the company’s stock, valued at approximately $25,214,130.61. The trade was a 3.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 55,890 shares of company stock valued at $3,111,189. 3.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Jupiter Topco LLC acquired a new position in Vaxcyte in the second quarter valued at about $1,044,355,000. Janus Henderson Group PLC raised its stake in Vaxcyte by 23.8% during the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after acquiring an additional 3,188,687 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Vaxcyte in the second quarter valued at approximately $701,520,000. T. Rowe Price Investment Management Inc. increased its stake in shares of Vaxcyte by 35.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after buying an additional 2,981,038 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Vaxcyte by 24.7% in the second quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company’s stock valued at $407,001,000 after buying an additional 1,386,968 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Trending Headlines about Vaxcyte

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Vaxcyte’s VAX-31 candidate delivered a positive Phase 3 result in the adult pneumococcal vaccine market. The late-stage win strengthens the case for VAX-31 and was viewed by some analysts as a potentially best-case outcome, improving confidence in the company’s path toward commercialization. Vaxcyte leaps on positive Phase III trial of VAX-31
• Positive Sentiment: Analyst support remains favorable. BTIG reaffirmed a Buy rating, while Needham assigned a $122 price target, substantially above recent trading levels. Additional VAX-31 data and other pipeline readouts are expected in the first half of 2027, providing potential future catalysts. BTIG Research Reaffirms Buy Rating for Vaxcyte
• Neutral Sentiment: Vaxcyte priced concurrent offerings totaling approximately $1 billion: about $500 million through common stock and pre-funded warrants at roughly $64 per share, plus $500 million of 1.50% convertible senior notes due 2032. The company can also sell additional securities underwriters’ over-allotment options. Proceeds should strengthen its balance sheet and fund VAX-31 development, manufacturing and other pipeline programs. Vaxcyte Announces Pricing of Concurrent Public Offerings
• Negative Sentiment: The equity component creates near-term dilution, while the convertible notes introduce potential future dilution if converted. The financing announcement overshadowed some of the clinical optimism and prompted a sharp retreat from the stock’s recent highs.
• Negative Sentiment: Unusually high put-option activity—8,093 contracts, reportedly 259% above typical volume—suggests increased hedging or bearish speculation, although options activity alone does not establish a fundamental change in Vaxcyte’s outlook.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.